If you gotta do the wrong thing, at least do it sustainably.
Beneath the golden blooms of Australia's national emblem, forensic chemists and clinical researchers have independently discovered the same quiet secret: certain wattle trees carry within their bark a compound that can dissolve the boundaries of the self. What began as a 2008 drug raid in Western Australia has grown into a broader reckoning — one that asks not only how nature hides its most potent molecules, but whether those molecules might one day heal the minds of millions. The story of DMT in the acacia is, at its heart, a story about the distance between prohibition and medicine, and how thin that line has always been.
- Criminal networks began stripping wattle bark across Perth after discovering it harboured DMT, flooding illegal labs with plant mulch and forcing forensic botanists into an urgent new role.
- The scale of the problem is vast — nearly 900 acacia species populate Western Australia alone, and only a handful of licensed scientists can legally determine which trees are being targeted and why.
- Clinical researchers are now racing to harness what criminals already knew, launching trials that test synthetic DMT against alcohol use disorder and major depression — conditions where conventional medicine routinely falls short.
- The compound works by quieting the brain's rigid self-narrative, opening a window in which trauma can be processed and new understanding can take root at a neurological level.
- Botanical harvesting has already been ruled out for therapeutic scale — the plant yields too little, and the world needs too much — leaving synthetic production as the only viable path to global medicine.
- A forensic botanist watching trees stripped bare offers the story's most unsettling resolution: if the illegal harvesting cannot be stopped, perhaps it can at least be made sustainable.
In 2008, forensic chemists raiding a clandestine Western Australian drug lab found something unexpected alongside the usual residues: piles of wet wattle bark, boiled down to extract DMT, the powerful psychedelic compound. Word moved quickly through criminal networks. Within years, plant mulch had become more common in Perth's illegal labs than methamphetamine residue.
Dr. Kelly Shepherd, a senior research scientist at the WA Herbarium — which holds over 845,000 preserved specimens — holds one of only two state licences to work with controlled substances in a botanical context. When police need bark identified, they call her. Working with colleagues at ChemCentre, she tested hundreds of preserved samples to map the problem. The findings were clarifying: DMT appears only in specific acacia species, likely inherited from a common genetic ancestor. What struck her most was not the criminality but the deeper mystery — that plants growing in remote landscapes carry extraordinary compounds that science has barely begun to understand.
On the clinical side, Associate Professor Daniel Perkins at the University of Melbourne's Psychedelics Research and Therapeutics Unit published the first trial using DMT synthesised from Australian acacia plants. Nine volunteers with prior psychedelic experience participated, reporting experiences consistent with ayahuasca — the traditional brew containing the same compound. The mechanism centres on a single serotonin receptor, 5HT2A, whose activation suppresses the brain's rigid top-down control and reshapes the default mode network, the neural architecture of selfhood. This creates a therapeutic window in which trauma can be processed and new understanding becomes deeply embedded.
Later this year, Perkins launches trials targeting alcohol use disorder and major depressive disorder — conditions where conventional treatments frequently fail. Yet the medicine will not come from wattle trees. With DMT concentrations of only 0.5 to 1.5 percent by weight, botanical extraction cannot scale to global therapeutic need. Synthetic production is the only viable path.
Shepherd, watching trees stripped bare across Perth, holds no illusion that illegal harvesting will stop. Her hope is more modest and more honest: that those determined to do it might at least be persuaded to do it sustainably.
In 2008, forensic investigators in Western Australia stumbled onto something unexpected while raiding a clandestine drug laboratory. Among the seized materials sat piles of wet bark, stripped from wattle trees and stewed down into a murky broth. The chemists at ChemCentre realized what they were looking at: someone had figured out how to extract dimethyltryptamine—DMT, the powerful psychedelic compound—from Australia's national emblem. Word spread through criminal networks. Within years, forensics teams in Perth were finding more plant mulch in illegal labs than methamphetamine residue.
Dr. Kelly Shepherd, a senior research scientist at the WA Herbarium, holds one of only two licenses in the state to work with controlled drugs in a botanical context. When police need bark identified from a drug lab, she's the person they call. The herbarium itself houses over 845,000 preserved plant specimens from across Western Australia, making it an ideal resource for understanding which species had become targets. "Acacias are almost ubiquitous in our landscape," Shepherd explains. "There are nearly 900 species here in WA alone." The question became urgent: how widespread was this problem, and which wattles actually contained the compound?
Shepherd and her colleagues at ChemCentre tested hundreds of preserved samples from the herbarium's collection. The results were clarifying but not entirely surprising. Not every wattle tree contains DMT—the compound appears only in specific species and their close relatives, likely the result of a genetic mutation inherited from a common ancestor rather than anything more mysterious. "The more interesting thing," Shepherd reflects, "is that these plants in the middle of nowhere have these interesting substances in them and we don't even know." It's a reminder of how much biodiversity remains chemically unmapped, and why preserving it matters.
Meanwhile, on the clinical side of the equation, researchers were beginning to ask what DMT actually does inside the human body. Daniel Perkins, an associate professor at the University of Melbourne's Psychedelics Research and Therapeutics Unit, published the first clinical trial using DMT extracted from Australian acacia plants—synthesized in a CSIRO facility, not a backyard operation. Nine healthy volunteers with prior psychedelic experience participated. Their reports aligned with what users of ayahuasca, which contains the same compound, typically describe. The mechanism is elegant: LSD, psilocybin, and DMT all work primarily through a single serotonin receptor called 5HT2A. When activated, this receptor triggers a cascade across the brain, suppressing the rigid top-down control that normally enforces fixed beliefs and altering the default mode network—the neural architecture underlying our sense of self.
What makes this neurological effect clinically interesting is not the recreational experience but the therapeutic potential. Psychedelics appear to create a window in which people can process trauma and develop new understandings that become deeply embedded. "You have this combination of effects that seem to work very well together," Perkins says, "to allow people to have these profound experiences, process trauma and then have changes in their understanding that become quite embedded." Later this year, his team launches a new trial testing DMT as a treatment for alcohol use disorder and major depressive disorder—conditions where conventional approaches often fail.
Yet there's an irony embedded in this story. While clinical medicine may soon offer psychedelics as treatment, it won't be harvesting them from wattle trees. Acacia bark contains only 0.5 to 1.5 percent DMT by weight, meaning extraction requires processing enormous quantities of plant material. For a medicine intended to reach millions of people globally, botanical sourcing becomes logistically and environmentally untenable. Perkins and his team have moved to synthetic production. Shepherd, watching the criminal labs strip bark from trees across Perth, harbors no illusions about stopping the illegal harvesting. Her pragmatic hope is smaller: "If people are going to take these plants to extract drugs, which they will do, then at least we might make some positive impact by telling them that sustainable harvesting would be better. If you gotta do the wrong thing, at least do it sustainably."
Citas Notables
These plants in the middle of nowhere have these interesting substances in them and we don't even know. That's one of the arguments we make about maintaining biodiversity.— Dr. Kelly Shepherd, WA Herbarium
You have this combination of effects that seem to work very well together to allow people to have these profound experiences, process trauma and then have changes in their understanding that become quite embedded.— Daniel Perkins, University of Melbourne Psychedelics Research and Therapeutics Unit
La Conversación del Hearth Otra perspectiva de la historia
How did someone figure out that wattle trees contained DMT in the first place?
It wasn't a botanist or a chemist working in a lab. It was someone in the criminal underworld who either knew the ethnobotanical literature or heard it through networks. Once one person figured it out and it worked, the knowledge spread fast. That's how forensics teams ended up finding wet bark in drug labs.
Why do only some wattle species contain it?
It's almost certainly a genetic accident—a mutation that happened in an ancestor and got passed down to a few related species. There's nothing special about DMT itself that makes it more likely to appear in acacias than anywhere else. It's just chance that these particular plants ended up with the machinery to make it.
But that raises a question: why do our brains have the receptor for it at all?
That's the deeper mystery. We have serotonin receptors because our brains use serotonin for all sorts of things—mood, perception, sleep. DMT just happens to fit that lock very well. Whether humans ever evolved to use DMT naturally is still an open question.
So the clinical trials are using synthetic DMT, not the plant extract?
Yes. The plant is only 0.5 to 1.5 percent DMT. To get a therapeutic dose, you'd need to process kilos of bark. For a medicine meant to treat millions of people, that's not scalable or sustainable. Synthetic is cleaner, more consistent, and doesn't require destroying forests.
Does that disappoint the botanists?
Kelly Shepherd isn't naive about it. She knows people will keep harvesting the trees illegally. Her position is pragmatic: if they're going to do it anyway, at least do it sustainably. It's a harm-reduction approach applied to plant poaching.
What happens next with the clinical research?
They're testing DMT for alcohol use disorder and major depression later this year. If it works the way early data suggests, we could see psychedelics in psychiatric clinics within a few years. The question then becomes regulatory and social—how do we integrate something this powerful into mainstream medicine?